Table 6. Age adjusted odds ratio for ≥CIN 2 of each HR-HPV group: HPV 16/18 (+) and the two stratified groups of non-16/18 HR-HPV (+)*.
| Variable | Total | ≥CIN 2 | Odds ratio† | 95% CI | p-value |
|---|---|---|---|---|---|
| HPV-16/18 (+) | 183 | 110 (60.7) | 18.117 | 11.599-28.296 | <0.001 |
| HPV-31/33/35/45/52/58 (+) | 158 | 79 (50.0) | 11.922 | 7.575-18.764 | <0.001 |
| HPV-39/51/56/59/66/68 (+) | 126 | 21 (16.7) | 2.404 | 1.350-4.283 | 0.003 |
| HR-HPV (-) | 522 | 40 (7.7) | - | - | |
| Overall | 989 | 250 (25.3) | - | - |
Values are presented as number (%).
CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; HR, high-risk.
*HPV-16/18 (+) includes HPV-16 (+) or HPV-18 (+); non-16/18 HR-HPV (+) includes HPV-16 (–) and HPV-18 (–), 12 other HR-HPV (+); 12 non-16/18 HR-HPV (+) were divided into two groups, one including HPV-39 (+) or HPV-51 (+) or HPV-56 (+) or HPV-59 (+) or HPV-66 (+) or HPV-68 (+), and the other including HPV-31 (+) or HPV-33 (+) or HPV-35 (+) or HPV-45 (+) or HPV-52 (+) or HPV-58 (+); HR-HPV (–), as a control, includes low-risk HPV (+) or 'HPV-other types' (+) or HPV (–). Multiple infection cases (n=113) were excluded.
†Odds ratio, age-controlled odds ratio for ≥CIN 2.